SCHEMBL3675608

SCHEMBL3675608

Oc1nc2ncc(Cl)cc2n1-c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
MAT2A P31153 8/20 0.39
FGFR1 P11362 2/20 0.38
MAPT P10636 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 2/20 0.37
KDM4E B2RXH2 1/20 0.37
KDM4A O75164 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
PRMT5 O14744 1/20 0.36
CYP1A2 P05177 1/20 0.36
AHR P35869 1/20 0.36
GUSB P08236 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3669844 0.77 ALDH1A1 (0.53) L3MBTL1KMT2ASMN1; SMN2HSD17B10KDM4E
SCHEMBL646265 0.75 FGFR1 (0.50) LMNAL3MBTL1MEN1KMT2AMAT2A
SCHEMBL3669088 0.73 MEN1 (0.40) LMNAMEN1KMT2AHSD17B10KDM4E
SCHEMBL3675313 0.73 MEN1 (0.40) LMNAMEN1KMT2AHSD17B10KDM4E
SCHEMBL3667745 0.72 BRD4 (0.40) L3MBTL1HSD17B10KDM4EKDM4AALDH1A1
SCHEMBL3666716 0.72 BRD4 (0.40) L3MBTL1HSD17B10KDM4EKDM4AALDH1A1
SCHEMBL3674290 0.72 SRC (0.37) L3MBTL1HSD17B10KDM4EKDM4AALDH1A1
SCHEMBL3672010 0.71 PPARG (0.36) L3MBTL1HSD17B10KDM4EKDM4AALDH1A1
SCHEMBL3670211 0.71 KDM4E (0.39) L3MBTL1SMN1; SMN2HSD17B10KDM4EKDM4A
SCHEMBL3670293 0.69 ACSS2 (0.39) L3MBTL1HSD17B10KDM4EKDM4AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851484-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2010-12-14 US claimed
EP-2139478-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS Cytokinetics, Incorporated (US) 2010-01-06 EP claimed
WO-2008121333-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED (US) 2008-10-09 WO claimed
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2008-10-02 US claimed
US-7851484-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2010-12-14 US disclosed
US-7851484-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2010-12-14 US disclosed
US-7851484-B2 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. (US) 2010-12-14 US disclosed
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2008-10-02 US disclosed
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2008-10-02 US disclosed
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods CYTOKINETICS, INC. 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242695-A1 Certain Chemical Entities, Compositions, and Methods TNNC1, TNNI3, TNNT2 LMNA 391/4885L3MBTL1 2636/4885MEN1 3647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.